IE00B91XRN20 - Common Stock
PROTHENA CORP PLC
NASDAQ:PRTA (10/11/2024, 8:21:20 PM)
After market: 16.36 -0.86 (-4.99%)17.22
+0.44 (+2.62%)
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
PROTHENA CORP PLC
77 Sir John Rogersons Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60
P: 35312362500
CEO: Gene G. Kinney
Employees: 173
Website: https://www.prothena.com/
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on PRTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: